MedTrace Logo

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

NCT03594682 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-07-20

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of two different administration methods of apatinib in NSCLC patients.

Conditions

  • NSCLC Stage IV
  • NSCLC Stage IIIB

Interventions

OTHER

Intervention/treatment

experimentalgroup initial dose： 1. 250mg qod 2. 250mg qd/500mg qd by turn 3. 500mg qd control group： 750mg qd

Sponsors & Collaborators

  • Beijing Chest Hospital

    lead OTHER

Principal Investigators

  • Li Baolan · Beijing Chest Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2019-07-31
Completion
2020-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03594682 on ClinicalTrials.gov